TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.

Based on these findings, we proposed the combination of ferroptosis inducer and TrkA inhibitor to synergistically exert anti-tumor effects, which may provide a new strategy for the clinical treatment of prostate cancer.